UroGen Pharma (URGN) Payables (2016 - 2026)

UroGen Pharma (URGN) has reported Payables for 11 consecutive years, with $35.3 million the latest figure, recorded in Q1 2026.

• Quarterly Payables rose 16.57% year-over-year to $35.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.3 million (up 16.57% YoY) and the FY2025 annual result came in at $27.7 million, up 1.04% from the prior year.
• Payables improved to $35.3 million in Q1 2026 per URGN's latest filing, from $27.7 million in the prior quarter.
• Over the last five years, Payables for URGN reached as high as $35.3 million in Q1 2026 and fell as low as $8.6 million in Q2 2022.
• A 5-year average of $20.2 million and a median of $18.2 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables slipped 16.39% — and 2023, when it soared 89.7%.
• Year by year, Payables stood at $12.4 million in 2022, then jumped by 33.55% to $16.5 million in 2023, then jumped by 65.87% to $27.4 million in 2024, then gained by 1.04% to $27.7 million in 2025, then advanced by 27.52% to $35.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $35.3 million, $27.7 million, and $26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.